basal-cell

VMAT with a custom 3D bolus treated nasal BCC with low early toxicity

Seven patients completed 60 Gy with no recurrences, grade ≥3 skin toxicity, fibrosis, cartilage necrosis, or nasal contour deformation at early follow-up.